Literature DB >> 1703204

Selective activation of gamma/delta + T cell clones by single anti-CD2 antibodies.

S Wesselborg1, O Janssen, K Pechhold, D Kabelitz.   

Abstract

The CD2 antigen is the target for an "alternative" T cell activation pathway. Numerous studies have demonstrated that pairs of monoclonal antibodies (mAbs) directed toward two different epitopes are required for activation of T cell receptor (TCR)-alpha/beta + T cells via CD2. We have now explored the activation of human TCR-gamma/delta + T cell clones by a panel of anti-CD2 mAbs directed against the sheep erythrocyte-binding (T11.1) epitope of CD2. Seven of seven gamma/delta + clones expressing different molecular forms of the TCR-gamma/delta responded to stimulation by a single anti-CD2 mAb (OKT11, 9E8, BW0110, M-T910) with IL-2 secretion and/or proliferation. Immobilization of anti-CD2 mAbs in microculture plates was essential for activation of gamma/delta + clones, which occurred in the absence of feeder cells. In addition to interleukin 2 (IL-2) production and proliferation, anti-CD2 mAbs also triggered cytotoxic effector activity in gamma/delta + clones as measured against FcR+ P815 target cells. In contrast to gamma/delta + clones (but in line with established data), none of five CD4+ or CD8+ TCR-alpha/beta + clones were activated by any of the tested individual anti-CD2 mAbs. Taken together, our results reveal a striking difference between cloned gamma/delta + and alpha/beta + T cells in that gamma/delta + T cells are selectively activated by a single anti-CD2 (T11.1) mAb, without need for the simultaneous signal of a second anti-CD2 mAb directed against another (T11.2 or T11.3) CD2 epitope.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703204      PMCID: PMC2118790          DOI: 10.1084/jem.173.2.297

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants.

Authors:  S Y Yang; S Chouaib; B Dupont
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

2.  Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.

Authors:  R L Bolhuis; R C Roozemond; R J van de Griend
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  Regulation by anti-CD2 monoclonal antibody of the activation of a human T cell clone induced by anti-CD3 or anti-T cell receptor antibodies.

Authors:  H Yssel; J P Aubry; R de Waal Malefijt; J E de Vries; H Spits
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

4.  Role of CD2 cross-linking in cytoplasmic calcium responses and T cell activation.

Authors:  J A Ledbetter; P S Rabinovitch; I Hellström; K E Hellström; L S Grosmaire; C H June
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

5.  Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2).

Authors:  A Peterson; B Seed
Journal:  Nature       Date:  1987 Oct 29-Nov 4       Impact factor: 49.962

Review 6.  The alternative pathway of T cell activation: biology, pathophysiology, and perspectives for immunopharmacology.

Authors:  S C Meuer; M M Roux; B Schraven
Journal:  Clin Immunol Immunopathol       Date:  1989-01

7.  Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only.

Authors:  P S Goedegebuure; D M Segal; E Braakman; R J Vreugdenhil; B A Van Krimpen; R J Van de Griend; R L Bolhuis
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

8.  Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation.

Authors:  S M Denning; D T Tuck; L W Vollger; T A Springer; K H Singer; B F Haynes
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

9.  T cell stimulation via the erythrocyte receptor. Synergism between monoclonal antibodies and phorbol myristate acetate without changes of free cytoplasmic Ca++ levels.

Authors:  W Holter; G F Fischer; O Majdic; H Stockinger; W Knapp
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

10.  A unique V-J-C-rearranged gene encodes a gamma protein expressed on the majority of CD3+ T cell receptor-alpha/beta- circulating lymphocytes.

Authors:  F Triebel; F Faure; M Graziani; S Jitsukawa; M P Lefranc; T Hercend
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

2.  Modulation of WC1, a lineage-specific cell surface molecule of gamma/delta T cells augments cellular proliferation.

Authors:  M D Hanby-Flarida; O J Trask; T J Yang; C L Baldwin
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

3.  Costimulatory signals for human T-cell activation induce nuclear translocation of pp19/cofilin.

Authors:  Y Samstag; C Eckerskorn; S Wesselborg; S Henning; R Wallich; S C Meuer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 4.  Engineering γδ T Cells: Recognizing and Activating on Their Own Way.

Authors:  Ruoyu Dong; Yixi Zhang; Haowen Xiao; Xun Zeng
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

5.  Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms.

Authors:  A Cesano; D Santoli
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

Review 6.  Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions.

Authors:  Malte Deseke; Immo Prinz
Journal:  Cell Mol Immunol       Date:  2020-07-24       Impact factor: 11.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.